TYRA financial statements
The full income statement, balance sheet, and cash-flow statement for Tyra Biosciences Inc. (TYRA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 133M+27.4% | 104M+30.3% | 79.9M+35.7% | 58.9M+124.2% | 26.3M+182.8% | ||
| Research & development | 103M+28.5% | 80.1M+28.1% | 62.5M+45.4% | 43.0M+108.4% | 20.6M+186.5% | |
| Selling, general & administrative | 29.8M+23.8% | 24.1M+38.3% | 17.4M+9.5% | 15.9M+181.7% | 5.65M+169.9% | |
| General & administrative | 29.8M+23.8% | 24.1M+38.3% | 17.4M+9.5% | 15.9M+181.7% | 5.65M+169.9% | |
| Operating income | -133M-27.4% | -104M-30.3% | -79.9M-35.7% | -58.9M-124.2% | -26.3M-182.8% | |
| Other non-operating income | 12.8M-27.6% | 17.7M+63.7% | 10.8M+200.1% | 3.60M+60133.3% | -6.00K+84.6% | |
| Income tax | 0.00 | 0.00 | 0.00-100.0% | 2.00K+100.0% | 1.00K+0.0% | |
| Net income | -120M-38.7% | -86.5M-25.1% | -69.1M-25.0% | -55.3M-110.4% | -26.3M-181.6% | |
| -$2.01-33.1% | -$1.51+6.8% | -$1.62-22.7% | -$1.32+30.9% | -$1.91 | ||
| EPS (basic) | -$2.01-33.1% | -$1.51+6.8% | -$1.62-22.7% | -$1.32+30.9% | -$1.91 | |
| Weighted-avg shares (basic) | 59.6M+4.2% | 57.2M+34.0% | 42.7M+2.0% | 41.9M+203.9% | 13.8M | |
| Weighted-avg shares (diluted) | 59.6M+4.2% | 57.2M+34.0% | 42.7M+2.0% | 41.9M+203.9% | 13.8M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 265M-23.6% | 347M+64.2% | 212M-17.7% | 257M-15.4% | 304M+1889.8% | ||
| Cash & equivalents | 77.4M-15.9% | 92.0M+58.5% | 58.0M-76.9% | 251M-16.9% | 302M+1884.9% | |
| Prepaid expenses | 9.45M+56.9% | 6.02M-26.6% | 8.20M+35.0% | 6.08M+224.0% | 1.88M+3189.5% | |
| 283M-22.3% | 364M+61.0% | 226M-15.1% | 266M-13.2% | 307M+1815.6% | ||
| Property, plant & equipment | 1.31M-20.4% | 1.65M+1.4% | 1.63M+51.2% | 1.08M+4.9% | 1.03M+245.8% | |
| Operating lease right-of-use | 5.57M | — | — | — | — | |
| Other non-current assets | 9.27M+25.7% | 7.38M+46.6% | 5.03M+15.7% | 4.35M+1294.2% | 312K+1385.7% | |
| 18.1M+24.0% | 14.6M-4.8% | 15.3M+169.0% | 5.70M+57.7% | 3.62M+94.6% | ||
| Accounts payable | 1.18M+99.7% | 590K-87.3% | 4.66M+307.2% | 1.15M+91.2% | 599K-9.8% | |
| Current lease liability | 472K+14.6% | 412K+47.1% | 280K+100.0% | 140K-30.7% | 202K+42.3% | |
| 23.4M+14.8% | 20.4M-5.5% | 21.6M+158.6% | 8.35M+68.3% | 4.96M+148.4% | ||
| Non-current lease liability | 5.34M-8.1% | 5.81M-6.5% | 6.22M+150.4% | 2.48M+153.0% | 981K | |
| Operating lease liability (total) | 5.81M-6.6% | 6.22M-4.2% | 6.50M+147.7% | 2.62M+121.6% | 1.18M | |
| Other non-current liabilities | 0.00-100.0% | 3.00K-93.5% | 46.0K-72.8% | 169K-54.0% | 367K+162.1% | |
| 259M-24.5% | 343M+68.0% | 204M-20.8% | 258M-14.6% | 302M+2312.5% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 5.00K+0.0% | 5.00K+25.0% | 4.00K+0.0% | 4.00K+0.0% | 4.00K | |
| Additional paid-in capital | 630M+6.1% | 594M+61.0% | 369M+4.3% | 354M+3.3% | 342M-22.1% | |
| Retained earnings | -371M-47.7% | -251M-52.5% | -165M-72.2% | -95.7M-137.0% | -40.4M-186.8% | |
| Accumulated other comprehensive income | 393K-49.0% | 770K+102.1% | 381K | 0.00 | — | |
| Total liabilities & equity | 283M-22.3% | 364M+61.0% | 226M-15.1% | 266M-13.2% | 307M+1815.6% | |
| Common shares issued | 53.7M+5.8% | 50.8M+17.8% | 43.1M+1.1% | 42.6M+0.2% | 42.5M+1294.3% | |
| Common shares outstanding | 53.7M+5.8% | 50.7M+18.0% | 43.0M+1.6% | 42.4M+2.2% | 41.4M+2165.3% | |
| Shares outstanding (cover) | 53.9M+1.5% | 53.1M+1.1% | 52.5M+23.8% | 42.4M+2.0% | 41.6M | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -95.1M-36.4% | -69.8M-39.2% | -50.1M+0.3% | -50.3M-111.8% | -23.7M-205.9% | ||
| Depreciation & amortization | 546K+5.2% | 519K+45.4% | 357K+20.6% | 296K+111.4% | 140K+197.9% | |
| Share-based compensation | 28.0M+22.8% | 22.8M+68.6% | 13.5M+27.7% | 10.6M+266.7% | 2.89M+557.6% | |
| 72.5M+173.6% | -98.4M+32.0% | -145M-25768.5% | -559K+13.3% | -645K-106.7% | ||
| Capital expenditure | 141K-78.8% | 664K-13.8% | 770K+37.7% | 559K-15.4% | 661K+111.9% | |
| Free cash flow | -95.3M-35.3% | -70.4M-38.4% | -50.9M-0.1% | -50.8M-108.3% | -24.4M-202.2% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Proceeds from sale of PP&E | — | — | — | 0.00-100.0% | 16.0K | |
| 8.10M-96.0% | 202M+13051.4% | 1.54M+143.2% | 632K-99.8% | 311M+1228.6% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -14.6M-142.9% | 34.0M+117.6% | -193M-284.8% | -50.2M-117.5% | 287M+1768.3% | |
| Interest paid | — | — | — | — | 0.00-100.0% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.42B+91.9% | 738M+23.7% | 596M+86.0% | 321M-45.2% | 585M | |
| P/B | 5.5×+154.1% | 2.2×-19.9% | 2.7×+124.1% | 1.2×-38.3% | 1.9× | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: TYRA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TYRA filings on SEC EDGAR → Not investment advice.